Literature DB >> 8958933

Regulation of experimental autoimmune encephalomyelitis by interleukin-12.

J P Leonard1, K E Waldburger, S J Goldman.   

Abstract

We have evaluated the effects of rmIL-12 on the course of adoptively transferred EAE. When mice were injected with LNC that had been stimulated in vitro with PLP in the presence of rmIL-12, the subsequent course of disease was more severe and prolonged than controls. In vitro stimulation with PLP in the presence of IL-12 was associated with an increase in IFN-gamma and decrease in IL-4-producing cells, indicating a preferential expansion of Th1 effector cells. At peak disease, no notable differences in either the cellular composition or cytokine expression within CNS lesions was seen between groups. However, the frequency of macrophages that stained positively for inducible nitric oxide synthase (iNOS) was increased in animals challenged with rmIL-12 treated LNC. These data suggest that in addition to promoting the preferential expansion of IFN-gamma-producing cells by rmIL-12 treatment in vitro, in vivo effects leading to macrophage activation and iNOS expression may contribute to the severe, protracted course of CNS inflammation in this model. In contrast, treatment of mice with an antibody to murine IL-12 following cell transfer completely prevented paralysis with only 40% of the mice developing mild disease. These data suggest that endogenous IL-12 plays a pivotal role in the pathogenesis of this model of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958933     DOI: 10.1111/j.1749-6632.1996.tb52671.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Masha Fridkis-Hareli; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

2.  Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

Authors:  Yi Chen; Claire L Langrish; Brent McKenzie; Barbara Joyce-Shaikh; Jason S Stumhofer; Terrill McClanahan; Wendy Blumenschein; Tatyana Churakovsa; Justin Low; Leonard Presta; Christopher A Hunter; Robert A Kastelein; Daniel J Cua
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

Review 3.  Regulatory mechanisms of helper T cell differentiation: new lessons learned from interleukin 17 family cytokines.

Authors:  Bhanu P Pappu; Pornpimon Angkasekwinai; Chen Dong
Journal:  Pharmacol Ther       Date:  2008-01-19       Impact factor: 12.310

4.  Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

Authors:  Masha Fridkis-Hareli; Laura Santambrogio; Joel N H Stern; Lars Fugger; Celia Brosnan; Jack L Strominger
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 5.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.

Authors:  Tanuja Chitnis; Samia J Khoury
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice.

Authors:  Masanori Matsui; Osamu Moriya; Maria Laura Belladonna; Sadahiro Kamiya; François A Lemonnier; Takayuki Yoshimoto; Toshitaka Akatsuka
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 7.  Th17 cells in immunity and autoimmunity.

Authors:  Simone Kennedy Bedoya; Brandon Lam; Kenneth Lau; Joseph Larkin
Journal:  Clin Dev Immunol       Date:  2013-12-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.